

Remarks

In the Office Action, the Examiner noted that claims 1 to 28 are subject to restriction. In particular, the Examiner has given a two-way restriction in accordance with 35 U.S.C. 121 as follows:

<i>Inventions</i>	<i>Class/Sub-class</i>
Group I. Claims 2-3, 11-12 and 21-22, drawn to a composition and a method for prevention or treatment of Alzheimer's disease comprising the formula (IA).	514/23
Group II. Claims 4-5, 13-14 and 23-24, drawn to a composition and a method for prevention or treatment of Alzheimer's disease comprising the formula (IB).	514/156

As indicated above, through this response, Applicants provisionally elect invention Group I *with traverse*, namely, claims 2-3, 11-12 and 21-22, drawn to a composition and a method for prevention or treatment of Alzheimer's disease comprising the formula IA. Examiner's imposition of two-way restriction is respectfully traversed below.

Applicants respectfully submit that this two-way restriction as imposed by the Examiner is improper because Applicants believe that there is no undue burden on the Examiner to search for all of the claims as they are in same class and differ only by a sub-class.

More specifically, Applicants respectfully submit that the search of all of the claims 1 to 28 should not impose any undue burden on the Examiner. In support of our assertion, we draw Examiner's attention to the Table shown above, which lists both groupings of the invention. However, as also noted by the Examiner, both groups of inventions are in same class of 514 and differ only by the sub-class, i.e., subclass 23 for Group I and subclass 156 for Group II. Thus it is submitted that both invention Groups can be searched together imposing no undue burden on the Examiner. Even more importantly, it should be noted that invention Group I is directed to compositions comprising compounds of formula IA suitable for the prevention or treatment of Alzheimer's. Whereas, invention Group II is directed to similar compositions albeit comprising a compound of formula (IB), again

useful for the same prevention or treatment of Alzheimer's. Thus it is submitted that when the Examiner is searching for invention Group I, that itself may facilitate the search of invention Groups II. Thus, it should not impose any undue burden on the Examiner to search both inventions together. Therefore, Applicants respectfully submit that both inventions be rejoined and examined together.

In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

Applicants believe there are no fees due for this response. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. **18-1982** for sanofi-aventis, U.S. LLC, Bridgewater, NJ. Please credit any overpayment to Deposit Account No. **18-1982**.

Respectfully submitted,

August 15, 2006



Balaram Gupta
Registration No. 40,009
Attorney for Applicants

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
MAIL STOP: BWD-303A
Bridgewater, NJ 08807-0800
Telephone: 908-231-3364
Telefax: 908-231-2626